(Reuters) – The U.S. Food and Drug Administration said on Friday it had approved Daiichi Sankyo Co Ltd and AstraZeneca Plc’s drug to treat an advanced form of breast cancer, three months ahead of schedule. AstraZeneca in March signed a licensing and collaborat... More »
(Reuters) – The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd’s treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs. The label for the treatment, Turalio, includes a boxed warning flaggi... More »
Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments. More »
